Biohaven (BHVN) reported results from a Phase 2 proof-of-concept study evaluating BHV-7000 for the treatment of major depressive disorder. The study did not meet its primary endpoint, a reduction of depressive symptoms as measured by change in the Montgomery Åsberg Depression Rating Scale over six weeks compared with placebo.
The company noted that trends favoring BHV-7000 were observed in some clinically relevant subgroups, including participants with more severe depression at screening and baseline, on primary and secondary outcome measures. Additional analyses are ongoing and the company plans to present the results at an upcoming scientific meeting.
Shares of Biohaven were down 16% after hours on Wednesday.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.